IP Library Patent Application 15338020
Patent Application
App. No. 15/338,020

THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/338,020
Abstract

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

Claims (16)

1 . A composition of matter comprising at least one harmine component and at least one isovanillin component, said at least one harmine component comprising harmaline and said at least one isovanillin comprising vanillin.

2 . The composition of claim 1 , said composition consisting essentially of harmaline and vanillin.

3 . The composition of claim 1 , wherein at least one of said components is in the form of an ester, metal complex, or pharmaceutically acceptable salt.

4 . The composition of claim 1 , said composition being an anti-cancer composition.

5 . The composition of claim 4 , said composition exhibiting anti-cancer effects against lymphoma, ovarian, and head and neck cancer cells.

6 . The composition of claim 1 , the ratio of said isovanillin component(s) to said harmine component(s) being from about 0.5:1 to 15:1.

7 . The composition of claim 1 , said isovanillin component(s) being present at a level of from about 25-95% by weight, and said harmine component(s) being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight.

8 . A method of treating a human patient suffering from cancer comprising the step of administering to the patient a composition in accordance with claim 1 .

9 . A method of killing or inhibiting the growth of cancer cells comprising the step of contacting the cells with a composition in accordance with claim 1 .

10 . The method of claim 9 , said composition exhibiting anti-cancer effects against lymphoma, ovarian, and head and neck cancer cells.

11 . A method of preparing a composition comprising the step of mixing together at least one harmine component and at least one isovanillin component, said at least one harmine component comprising harmaline and said at least one isovanillin comprising vanillin.

12 . The method of claim 10 , comprising the step of mixing together harmaline and vanillin.

13 . The method of claim 11 , the ratio of said isovanillin component(s) to said harmine component(s) being from about 0.5:1 to 15:1.

14 . The method of claim 11 , said isovanillin component(s) being present at a level of from about 25-95% by weight, and said harmine component(s) being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight.

15 . The method of claim 11 , including the step of mixing said components in ethanol, and sonicating the mixture.

16 . A product prepared by the method of claim 11 .

Assignments (2)
MERGER Recorded Aug 30, 2018
From: IONS PHARMACEUTICAL S.A R.L.
To: ANKH LIFE SCIENCES LIMITED
Reel/Frame 046760/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2016
From: ZAID, GENE H.; BURGOYNE, THOMAS W.; GENZADA PHARMACEUTICALS LLC
To: IONS PHARMACEUTICAL S.À R.L.
Reel/Frame 040174/0047 →